Evidence map›Paper›PMID 37883464›Full record

ArticleHuman molecular genetics2024

Characterizing and predicting ccRCC-causing missense mutations in Von Hippel-Lindau disease.

Adam Serghini, Stephanie Portelli, Guillaume Troadec, Catherine Song, Qisheng Pan, Douglas E V Pires, David B Ascher

Open access · hybridAbstract read
In one paragraph

Article in Human molecular genetics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Rescuing the Function of Missense-Mutated Tumor SuppressorbioRxiv : the preprint server for biology · 2026
    Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Adam SerghiniSchool of Chemistry and Molecular Biosciences, Chemistry Building 68, Cooper Road, The University of Queensland, St Lucia, QLD 4072, Queensland, Australia.
Stephanie PortelliSchool of Chemistry and Molecular Biosciences, Chemistry Building 68, Cooper Road, The University of Queensland, St Lucia, QLD 4072, Queensland, Australia.
Guillaume TroadecSchool of Computing and Information Systems, University of Melbourne, Melbourne, VIC 3010, Australia.
Catherine SongSchool of Computing and Information Systems, University of Melbourne, Melbourne, VIC 3010, Australia.
Qisheng PanSchool of Chemistry and Molecular Biosciences, Chemistry Building 68, Cooper Road, The University of Queensland, St Lucia, QLD 4072, Queensland, Australia.
Douglas E V PiresSchool of Computing and Information Systems, University of Melbourne, Melbourne, VIC 3010, Australia.ORCID 0000-0002-3004-2119
David B AscherSchool of Chemistry and Molecular Biosciences, Chemistry Building 68, Cooper Road, The University of Queensland, St Lucia, QLD 4072, Queensland, Australia.ORCID 0000-0003-2948-2413
Baker Heart and Diabetes Institute · AUThe University of Melbourne · AUThe University of Queensland · AU

Funding

National Health and Medical Research Council GNT1174405Victorian Government's Operational Infrastructure Support Program
6 · The paper itself

Abstract

backgroundMutations within the Von Hippel-Lindau (VHL) tumor suppressor gene are known to cause VHL disease, which is characterized by the formation of cysts and tumors in multiple organs of the body, particularly clear cell renal cell carcinoma (ccRCC). A major challenge in clinical practice is determining tumor risk from a given mutation in the VHL gene. Previous efforts have been hindered by limited available clinical data and technological constraints.

methodsTo overcome this, we initially manually curated the largest set of clinically validated VHL mutations to date, enabling a robust assessment of existing predictive tools on an independent test set. Additionally, we comprehensively characterized the effects of mutations within VHL using in silico biophysical tools describing changes in protein stability, dynamics and affinity to binding partners to provide insights into the structure-phenotype relationship. These descriptive properties were used as molecular features for the construction of a machine learning model, designed to predict the risk of ccRCC development as a result of a VHL missense mutation.

resultsAnalysis of our model showed an accuracy of 0.81 in the identification of ccRCC-causing missense mutations, and a Matthew's Correlation Coefficient of 0.44 on a non-redundant blind test, a significant improvement in comparison to the previous available approaches.

conclusionThis work highlights the power of using protein 3D structure to fully explore the range of molecular and functional consequences of genomic variants. We believe this optimized model will better enable its clinical implementation and assist guiding patient risk stratification and management.

Indexed as

Machine LearningMutation, Missensevon Hippel-Lindau DiseaseCarcinoma, Renal CellHumansKidney NeoplasmsVon Hippel-Lindau Tumor Suppressor ProteinVon Hippel-Lindau Tumor Suppressor ProteinccRCCclear cell renal cell carcinomamachine learningVHLVon Hippel-Lindau

Identifiers

PMID37883464
PMCPMC10800015
OpenAlexW4387966267

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.